ICP
GILD icon

Interchange Capital Partners’s Gilead Sciences GILD Stock Holding History

Interchange Capital Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,500
Closed -$139K – 308
2024
Q4 		$139K Hold
1,500
– – 0.05% 249
2024
Q3 		$126K Hold
1,500
– – 0.04% 259
2024
Q2 		$103K Buy
+1,500
New +$100K 0.04% 264
2023
Q2 		– Sell
-300
Closed -$24.9K – 174
2023
Q1 		$24.9K Buy
+300
New +$24.8K 0.01% 217

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Interchange Capital Partners's GILD Position: Q2 2026 in Review

Interchange Capital Partners increased its Gilead Sciences (GILD) stake by 77% in Q2 2026, buying an estimated $308K and bringing the position to 5,395 shares worth $682K. The position accounts for 0.13% of the portfolio, ranked #162.

Interchange Capital Partners first reported a position in GILD in Q4 2020 and has held it in 10 quarters since. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Interchange Capital Partners held 5,395 shares of Gilead Sciences worth $682K as of Q2 2026.
  • Interchange Capital Partners bought 2,341 Gilead Sciences shares in Q2 2026, an estimated $308K.
  • Gilead Sciences made up 0.13% of Interchange Capital Partners's portfolio in Q2 2026, its #162 holding.
  • Interchange Capital Partners first reported a position in Gilead Sciences in Q4 2020 and has held it in 10 quarters since.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Interchange Capital Partners's 13F filing for Q2 2026, filed 20 Jul 2026.